Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.

Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R, Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S, Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT.

Cancer Res. 2018 Jul 15;78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. Epub 2018 May 15.

2.

Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice.

Belmar NA, Chan SW, Fox MI, Samayoa JA, Stickler MM, Tran NN, Akamatsu Y, Hollenbaugh D, Harding FA, Alvarez HM.

J Immunol. 2017 Jun 1;198(11):4502-4512. doi: 10.4049/jimmunol.1601512. Epub 2017 Apr 26.

3.

Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.

Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K, Patil N, Levin A, Hsu AW, Charych D, Brennan T, Zanghi J, Halenbeck R, Marshall SA, Qin M, Doberstein SK, Hollenbaugh D, Kavanaugh WM, Williams LT, Baker KP.

Sci Transl Med. 2013 Mar 27;5(178):178ra39. doi: 10.1126/scitranslmed.3005414.

4.

Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996.

Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC.

J Immunol. 2011 Mar 1;186(5):2693-7. No abstract available.

5.

Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation.

Gilson CR, Milas Z, Gangappa S, Hollenbaugh D, Pearson TC, Ford ML, Larsen CP.

J Immunol. 2009 Aug 1;183(3):1625-35. doi: 10.4049/jimmunol.0900339. Epub 2009 Jul 10.

6.

Discovery of a cytokine and its receptor by functional screening of the extracellular proteome.

Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT.

Science. 2008 May 9;320(5877):807-11. doi: 10.1126/science.1154370.

7.

Construction of immunoglobulin fusion proteins.

Hollenbaugh D, Aruffo A.

Curr Protoc Immunol. 2002 May;Chapter 10:Unit 10.19A. doi: 10.1002/0471142735.im1019as48.

PMID:
18432866
8.

Use of monoclonal antibodies for expression cloning.

Hollenbaugh D, Aruffo A, Jones B, Linsley P.

Curr Protoc Immunol. 2001 May;Chapter 10:Unit 10.18. doi: 10.1002/0471142735.im1018s31. Review.

PMID:
18432683
9.

Use of monoclonal antibodies for expression cloning.

Hollenbaugh D, Aruffo A, Jones B, Linsley P.

Curr Protoc Mol Biol. 2003 May;Chapter 6:Unit 6.11. doi: 10.1002/0471142727.mb0611s62.

PMID:
18265331
10.

De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold.

Potin D, Launay M, Nicolai E, Fabreguette M, Malabre P, Caussade F, Besse D, Skala S, Stetsko DK, Todderud G, Beno BR, Cheney DL, Chang CJ, Sheriff S, Hollenbaugh DL, Barrish JC, Iwanowicz EJ, Suchard SJ, Dhar TG.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1161-4.

PMID:
15686933
11.

Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival.

Adams AB, Shirasugi N, Jones TR, Durham MM, Strobert EA, Cowan S, Rees P, Hendrix R, Price K, Kenyon NS, Hagerty D, Townsend R, Hollenbaugh D, Pearson TC, Larsen CP.

J Immunol. 2005 Jan 1;174(1):542-50.

12.

3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships.

Dhar TG, Shen Z, Gu HH, Chen P, Norris D, Watterson SH, Ballentine SK, Fleener CA, Rouleau KA, Barrish JC, Townsend R, Hollenbaugh DL, Iwanowicz EJ.

Bioorg Med Chem Lett. 2003 Oct 20;13(20):3557-60.

PMID:
14505670
13.

Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety.

Iwanowicz EJ, Watterson SH, Guo J, Pitts WJ, Murali Dhar TG, Shen Z, Chen P, Gu HH, Fleener CA, Rouleau KA, Cheney DL, Townsend RM, Hollenbaugh DL.

Bioorg Med Chem Lett. 2003 Jun 16;13(12):2059-63.

PMID:
12781195
14.

Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors.

Chen P, Norris D, Haslow KD, Murali Dhar TG, Pitts WJ, Watterson SH, Cheney DL, Bassolino DA, Fleener CA, Rouleau KA, Hollenbaugh DL, Townsend RM, Barrish JC, Iwanowicz EJ.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1345-8.

PMID:
12657279
15.

Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3.

Watterson SH, Dhar TG, Ballentine SK, Shen Z, Barrish JC, Cheney D, Fleener CA, Rouleau KA, Townsend R, Hollenbaugh DL, Iwanowicz EJ.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1273-6.

PMID:
12657262
16.

Quinolone-based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues.

Dhar TG, Watterson SH, Chen P, Shen Z, Gu HH, Norris D, Carlsen M, Haslow KD, Pitts WJ, Guo J, Chorba J, Fleener CA, Rouleau KA, Townsend R, Hollenbaugh D, Iwanowicz EJ.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):547-51.

PMID:
12565969
17.

Novel inhibitors of IMPDH: a highly potent and selective quinolone-based series.

Watterson SH, Carlsen M, Dhar TG, Shen Z, Pitts WJ, Guo J, Gu HH, Norris D, Chorba J, Chen P, Cheney D, Witmer M, Fleener CA, Rouleau K, Townsend R, Hollenbaugh DL, Iwanowicz EJ.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):543-6.

PMID:
12565968
18.

Anti-CD40 therapy extends renal allograft survival in rhesus macaques.

Pearson TC, Trambley J, Odom K, Anderson DC, Cowan S, Bray R, Lin A, Hollenbaugh D, Aruffo A, Siadak AW, Strobert E, Hennigar R, Larsen CP.

Transplantation. 2002 Oct 15;74(7):933-40.

PMID:
12394833
19.

The TosMIC approach to 3-(oxazol-5-yl) indoles: application to the synthesis of indole-based IMPDH inhibitors.

Dhar TG, Shen Z, Fleener CA, Rouleau KA, Barrish JC, Hollenbaugh DL, Iwanowicz EJ.

Bioorg Med Chem Lett. 2002 Nov 18;12(22):3305-8.

PMID:
12392738
20.

A survey of cyclic replacements for the central diamide moiety of inhibitors of inosine monophosphate dehydrogenase.

Dhar TG, Liu C, Pitts WJ, Guo J, Watterson SH, Gu H, Fleener CA, Rouleau K, Sherbina NZ, Barrish JC, Hollenbaugh D, Iwanowicz EJ.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3125-8.

PMID:
12372516
21.

Novel guanidine-based inhibitors of inosine monophosphate dehydrogenase.

Iwanowicz EJ, Watterson SH, Liu C, Gu HH, Mitt T, Leftheris K, Barrish JC, Fleener CA, Rouleau K, Sherbina NZ, Hollenbaugh DL.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):2931-4.

PMID:
12270177
22.

Novel amide-based inhibitors of inosine 5'-monophosphate dehydrogenase.

Watterson SH, Liu C, Dhar TG, Gu HH, Pitts WJ, Barrish JC, Fleener CA, Rouleau K, Sherbina NZ, Hollenbaugh DL, Iwanowicz EJ.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):2879-82.

PMID:
12270168
23.

Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase.

Pitts WJ, Guo J, Dhar TG, Shen Z, Gu HH, Watterson SH, Bednarz MS, Chen BC, Barrish JC, Bassolino D, Cheney D, Fleener CA, Rouleau KA, Hollenbaugh DL, Iwanowicz EJ.

Bioorg Med Chem Lett. 2002 Aug 19;12(16):2137-40.

PMID:
12127522
24.

Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity.

Dhar TG, Shen Z, Guo J, Liu C, Watterson SH, Gu HH, Pitts WJ, Fleener CA, Rouleau KA, Sherbina NZ, McIntyre KW, Shuster DJ, Witmer MR, Tredup JA, Chen BC, Zhao R, Bednarz MS, Cheney DL, MacMaster JF, Miller LM, Berry KK, Harper TW, Barrish JC, Hollenbaugh DL, Iwanowicz EJ.

J Med Chem. 2002 May 23;45(11):2127-30. Erratum in: J Med Chem2002 Nov 7;45(23):5188.

PMID:
12014950
25.

Novel diamide-based inhibitors of IMPDH.

Gu HH, Iwanowicz EJ, Guo J, Watterson SH, Shen Z, Pitts WJ, Dhar TG, Fleener CA, Rouleau K, Sherbina NZ, Witmer M, Tredup J, Hollenbaugh D.

Bioorg Med Chem Lett. 2002 May 6;12(9):1323-6.

PMID:
11965381
26.

Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates.

Adams AB, Shirasugi N, Durham MM, Strobert E, Anderson D, Rees P, Cowan S, Xu H, Blinder Y, Cheung M, Hollenbaugh D, Kenyon NS, Pearson TC, Larsen CP.

Diabetes. 2002 Feb;51(2):265-70.

27.

Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease.

Aruffo A, Hollenbaugh D.

Curr Opin Immunol. 2001 Dec;13(6):683-6. Review.

PMID:
11677090
28.

CD40L is critical for protection from demyelinating disease and development of spontaneous remyelination in a mouse model of multiple sclerosis.

Drescher KM, Zoecklein LJ, Pavelko KD, Rivera-Quinones C, Hollenbaugh D, Rodriguez M.

Brain Pathol. 2000 Jan;10(1):1-15.

PMID:
10668891
29.

Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens.

Pérez-Melgosa M, Hollenbaugh D, Wilson CB.

J Immunol. 1999 Aug 1;163(3):1123-7.

30.

The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo.

Niimi M, Pearson TC, Larsen CP, Alexander DZ, Hollenbaugh D, Aruffo A, Linsley PS, Thomas E, Campbell K, Fanslow WC, Geha RS, Morris PJ, Wood KJ.

J Immunol. 1998 Nov 15;161(10):5331-7.

31.

Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome.

Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, Ochs HD.

Blood. 1998 Oct 1;92(7):2421-34.

32.

Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome.

Leiva LE, Junprasert J, Hollenbaugh D, Sorensen RU.

J Clin Immunol. 1998 Jul;18(4):283-90.

PMID:
9710745
33.
34.

Development of an immunoassay for BMS-191352, a single-chain immunotoxin, and its application to toxicokinetic studies.

Damle B, Hollenbaugh D, Timoszyk J, Tay L, Kaul S.

J Immunoassay. 1998 May-Aug;19(2-3):145-65.

PMID:
9682129
35.

Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade.

Elwood ET, Larsen CP, Cho HR, Corbascio M, Ritchie SC, Alexander DZ, Tucker-Burden C, Linsley PS, Aruffo A, Hollenbaugh D, Winn KJ, Pearson TC.

Transplantation. 1998 Jun 15;65(11):1422-8.

PMID:
9645796
36.

Sulfated galactocerebrosides as potential antiinflammatory agents.

Marinier A, Martel A, Banville J, Bachand C, Remillard R, Lapointe P, Turmel B, Menard M, Harte WE Jr, Wright JJ, Todderud G, Tramposch KM, Bajorath J, Hollenbaugh D, Aruffo A.

J Med Chem. 1997 Sep 26;40(20):3234-47.

PMID:
9379443
37.

Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.

Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD.

Blood. 1997 Oct 1;90(7):2680-9.

38.

Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.

Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D.

J Immunol. 1997 Oct 1;159(7):3104-8.

PMID:
9317105
39.

BMS-190394, a selectin inhibitor, prevents rat cutaneous inflammatory reactions.

Todderud G, Nair X, Lee D, Alford J, Davern L, Stanley P, Bachand C, Lapointe P, Marinier A, Martel A, Menard M, Wright JJ, Bajorath J, Hollenbaugh D, Aruffo A, Tramposch KM.

J Pharmacol Exp Ther. 1997 Sep;282(3):1298-304.

PMID:
9316838
40.

Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice.

Clegg CH, Rulffes JT, Haugen HS, Hoggatt IH, Aruffo A, Durham SK, Farr AG, Hollenbaugh D.

Int Immunol. 1997 Aug;9(8):1111-22.

PMID:
9263008
41.

Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.

Kay MA, Meuse L, Gown AM, Linsley P, Hollenbaugh D, Aruffo A, Ochs HD, Wilson CB.

Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4686-91.

42.

Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5.

Ledbetter JA, Francisco JA, Siegall CB, Gilliland LK, Hollenbaugh D, Aruffo A, Siadak AW, Mischel-Petty N, Grosmaire LS, Gordon ML, Brown TJ, Moran-Davis P, Mittler RS, Kiener PA, Nadler SG.

Crit Rev Immunol. 1997;17(5-6):427-35. Review.

PMID:
9419430
43.

CD40 is functionally expressed on human keratinocytes.

Denfeld RW, Hollenbaugh D, Fehrenbach A, Weiss JM, von Leoprechting A, Mai B, Voith U, Schöpf E, Aruffo A, Simon JC.

Eur J Immunol. 1996 Oct;26(10):2329-34.

PMID:
8898941
44.

CD40 ligand triggers interleukin-6 mediated B cell differentiation.

Urashima M, Chauhan D, Hatziyanni M, Ogata A, Hollenbaugh D, Aruffo A, Anderson KC.

Leuk Res. 1996 Jun;20(6):507-15.

PMID:
8709623
45.

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.

Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC.

Nature. 1996 May 30;381(6581):434-8.

PMID:
8632801
46.
47.

CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway.

Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A, Hendrix R, Pearson TC.

Transplantation. 1996 Jan 15;61(1):4-9.

PMID:
8560571
48.

Cleavable CD40Ig fusion proteins and the binding to sgp39.

Hollenbaugh D, Douthwright J, McDonald V, Aruffo A.

J Immunol Methods. 1995 Dec 15;188(1):1-7.

PMID:
8551028
49.
50.

Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes.

Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D.

J Immunol. 1995 Nov 15;155(10):4917-25.

PMID:
7594496

Supplemental Content

Loading ...
Support Center